Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;94(9):1198-202.
doi: 10.3324/haematol.2009.009274.

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

Alan G Ramsay, John G Gribben
Review

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug

Alan G Ramsay et al. Haematologica. 2009 Sep.

Abstract

A new agent that is being used in chronic lymphocytic leukemia (CLL) and is receiving considerable interest is the immunomodulatory drug lenalidomide. The precise anti-CLL mechanism of action of lenalidomide is not yet completely defined. In this perspective article, Drs. Ramsay and Gribben examine the multiple biological effects of lenalidomide on various cell targets that likely contribute to its anti-CLL activity. See related paper on page 1266.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Lenalidomide repairs chronic lymphocytic leukemia T-cell immune synapse dysfunction. Treatment of both chronic lymphocytic leukemia cells and autologous T cells is required to enhance immunological synapse formation and T-cell functional signaling.
Figure 2.
Figure 2.
Lenalidomide restores T-cell actin cytoskeletal signaling (synapse formation and functional activity) and enhances antigen-presenting function of chronic lymphocytic leukemia cells (upregulation of co-stimulatory molecules). NK-mediated ADCC of rituximab-treated chronic lymphocytic leukemia cells is enhanced by pre-incubation of NK cells with lenalidomide before exposure to rituximab-exposed chronic lymphocytic leukemia cells. The immunomodulatory effect of lenalidomide on stromal cells and angiogenic status remains to be fully elucidated.
See this image and copyright information in PMC

References

    1. Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975–80. - PMC - PubMed
    1. Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood. 2007;110:2811–8. - PubMed
    1. Gribben JG. Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2008;15(1 Suppl):53–8. - PMC - PubMed
    1. Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood. 2002;100:167–73. - PubMed
    1. Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002;100:2123–31. - PubMed

MeSH terms